Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All azvudine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAzvudineAzvudine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 91% Improvement Relative Risk Hospitalization 75% Recovery 16% Azvudine for COVID-19  Yang et al.  EARLY TREATMENT Is early treatment with azvudine beneficial for COVID-19? Retrospective 804 patients in China (December 2022 - January 2023) Lower hospitalization with azvudine (p=0.047) c19early.org Yang et al., J. Medical Virology, July 2023 Favors azvudine Favors control

Oral azvudine for mild‐to‐moderate COVID‐19 in high risk, nonhospitalized adults: Results of a real‐world study

Yang et al., Journal of Medical Virology, doi:10.1002/jmv.28947
Jul 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Azvudine for COVID-19
39th treatment shown to reduce risk in May 2023
 
*, now known with p = 0.000076 from 13 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
PSM retrospective 804 high-risk, nonhospitalized adults with mild to moderate COVID-19 in China. The study compared outcomes between 317 patients who received azvudine with 487 patients who received standard supportive treatment only. The azvudine group had a lower rate of disease progression (composite of death or COVID-19 hospitalization) at 28 days, as well as a lower rate of COVID-19 hospitalization specifically after adjusting for factors. In addition, azvudine shortened the duration of fever if given within 3 days of symptom onset. However, azvudine treatment was associated with a higher incidence of adverse effects, including mainly mild gastrointestinal and nervous system effects.
risk of death, 90.8% lower, RR 0.09, p = 0.09, treatment 0 of 317 (0.0%), control 6 of 487 (1.2%), NNT 81, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of hospitalization, 74.8% lower, RR 0.25, p = 0.047, treatment 317, control 487, propensity score weighting.
risk of no recovery, 16.0% lower, RR 0.84, p = 0.19, treatment 317, control 487, propensity score weighting.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Yang et al., 20 Jul 2023, retrospective, China, peer-reviewed, 11 authors, study period 19 December, 2022 - 5 January, 2023. Contact: anzhuoling@bjcyh.com, tongzhaohuicy@sina.com.
This PaperAzvudineAll
Oral azvudine for mild‐to‐moderate COVID‐19 in high risk, nonhospitalized adults: Results of a real‐world study
Hui Yang, Zhaojian Wang, Chunguo Jiang, Yi Zhang, Ying Zhang, Man Xu, Yi Zhang, Yushu Wang, Xuefeng Liu, Zhuoling An, Zhaohui Tong
Journal of Medical Virology, doi:10.1002/jmv.28947
Azvudine is recommended by Chinese health authorities for COVID-19 treatment but has not been tested in real-world clinical studies. This study aimed to evaluate the realworld effectiveness of Azvudine among COVID-19 nonhospitalized patients. This was a retrospective cohort study, looking at nonhospitalized patients who tested positive for SARS-CoV-2. Patients admitted between December 19, 2022 and January 5, 2023 were included. Those who received Azvudine treatment were in the Azvudine group, while those who received supportive treatment were the control group. The primary outcome was the disease progression rate by Day 28. Secondary outcomes were individual disease progression outcomes (death or COVID-19-related hospitalization) and duration of fever. The safety outcomes were assessed based on adverse events (AEs) overall, as well as AEs that were considered to be related to the drug. A total of 804 patients with high risk for progression were enrolled in our study. Among them, 317 (39.43%) received treatment with Azvudine. Our study found that Azvudine could reduce the rate of disease progression, as well as rate of COVID-19-related hospitalization in patients comparing the control group. Furthermore, if taken within 3 days of the onset of symptoms, it could also shorten the duration of fever. Despite a higher incidence of drug-related AEs compared to supportive treatment, the majority of these were mild. Azvudine has been found to be effective in reducing the rate of disease progression of COVID-19, albeit with a slight increase in AEs.
AUTHOR CONTRIBUTIONS Zhuoling An and Zhaohui Tong designed the experiments. Chunguo Jiang was responsible for clinical assessment of patients. Hui Yang, Zhaojian Wang, Yi Zhang, Man Xu, Ying Zhang, Yushu Wang, and Yi Zhang collected the data. Zhaojian Wang was responsible for data management. Hui Yang and Zhaojian Wang conducted the statistical analysis. This article was written by Hui Yang, and reviewed by Xuefeng Liu, Zhuoling An, and Zhaohui Tong. All authors reviewed the article. CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interest. SUPPORTING INFORMATION Additional supporting information can be found online in the Supporting Information section at the end of this article.
References
Burki, Omicron variant and booster COVID-19 vaccines, Lancet Respir Med
Callaway, Omicron likely to weaken COVID vaccine protection, Nature
Cao, Gao, Bao, VV116 versus Nirmatrelvir-ritonavir for oral treatment of Covid-19, N Engl J Med
Collie, Champion, Moultrie, Bekker, Gray, Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa, N Engl J Med
Cui, Liu, Wang, Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron, Cell
Da Silva, Abreu Cabral, Souza, Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19, Frontiers in Medicine
Desai, Franklin, Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners, BMJ
Gentile, Scotto, Moriello, Nirmatrelvir/ritonavir and molnupiravir in the treatment of mild/moderate COVID-19: results of a real-life study, Vaccines
Hammond, Leister-Tebbe, Gardner, Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19, N Engl J Med
Kaabi, Zhang, Xia, Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial, JAMA
Lamontagne, Agarwal, Rochwerg, A living WHO guideline on drugs for Covid-19, BMJ
Ren, Luo, Yu, A randomized, open-label, controlled clinical trial of azvudine tablets in the treatment of mild and common COVID-19, a pilot study, Adv Sci
Sun, Peng, Yu, Mechanistic insight into antiretroviral potency of 2′-deoxy-2′-β-fluoro-4′-azidocytidine (FNC) with a Long-Lasting effect on HIV-1 prevention, J Med Chem
Vitiello, Ferrara, Auti, Domenico, Boccellino, Advances in the Omicron variant development, J Intern Med
Xia, Duan, Zhang, Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials, JAMA
Xia, Zhang, Wang, Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial, Lancet Infect Dis
Yu, Chang, Azvudine (FNC): a promising clinical candidate for COVID-19 treatment, Signal Transduct Target Ther
Yu, Chang, The first Chinese oral anti-COVID-19 drug azvudine launched, Innovation
Zhang, Li, Wang, Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients, Signal Transduct Target Ther
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit